Publications & background
Publications on our programs and background literature on our approach and targets
-
Cardiovascular Drugs and Therapy
August 2023
A First-in-Human Study of AMG 986, a Novel Apelin Receptor Agonist, in Healthy Subjects and Heart Failure Patients
August 2023
-
Drugs in R&D
April 2022
Evaluation of the Pharmacokinetics and Safety of AMG 986 Tablet and Capsule Formulations in Healthy Adult Subjects: A Phase I, Open-Label, Randomized Study
April 2022
-
Clinical Pharmacology in Drug Development
March 2022
A Phase 1, Open-Label Study to Evaluate the Effect of Food and Concomitant Itraconazole Administration on the Pharmacokinetics of AMG 986 in Healthy Subjects
March 2022
-
Drugs in R&D
March 2022
A Phase I, Open-label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of AMG 986 in Healthy Japanese Subjects
March 2022
-
Drugs in R&D
January 2022
Effect of Severe Renal Impairment on the Safety, Tolerability, and Pharmacokinetics of AMG 986
January 2022
-
JCI Insight
April 2020
Cardiovascular response to small-molecule APJ activation
April 2020
